Letter: Low Uptake of HIV Pre-Exposure Prophylaxis Despite Pharmacist-Managed Services in a Midwestern Federally Qualified Health Center

1.Centers for Disease Control and Prevention. HIV Surveillance Report: Diagnoses, Deaths, and Prevalence of HIV in the United States and 6 Territories and Freely Associated States, 2022. HIV Surveillance Report 2024;35. Available from: http://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-prevalence.html

2.U.S. Department of Health and Human Services. Ending the HIV Epidemic. Available from: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview/ [Last accessed: February 22, 2024].

3. Broekhuis JM , Scarsi KK , Sayles HR , et al. Midwest pharmacists’ familiarity, experience, and willingness to provide pre-exposure prophylaxis (PrEP) for HIV. PLoS One 2018;13(11):e0207372; doi: 10.1371/journal.pone.0207372

4. Havens JP , Scarsi KK , Sayles H , et al. Acceptability and feasibility of a pharmacist-led human immunodeficiency virus pre-exposure prophylaxis program in the Midwestern United States. Open Forum Infect Dis 2019;6(10):ofz365; doi: 10.1093/ofid/ofz365

5. Gagnon KW , Coulter RWS , Egan JE , et al. Facilitators, barriers, and opportunities to implementing sexual history screening and human immunodeficiency virus pre-exposure prophylaxis at a federally qualified health center. AIDS Patient Care STDS 2024;38(5):230–237; doi: 10.1089/apc.2024.0026

6. Arnold T , Whiteley L , Giorlando KK , et al. A qualitative study identifying implementation strategies using the i-PARIHS framework to increase access to pre-exposure prophylaxis at federally qualified health centers in Mississippi. Implement Sci Commun 2024;5(1):92; doi: 10.1186/s43058-024-00632-6

7. Riley T , Anaya G , Gallegos PA , et al. Pre-exposure prophylaxis use and discontinuation in a federally qualified health center in a Mexico-US Border City. J Racial Ethn Health Disparities. Published online October 32024;11(6):3537–3543; doi: 10.1007/s40615-023-01807-y

8.Centers for Disease Control and Prevention: US Public Health Service. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States - 2021 Update . 2021. Available from: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf [Last accessed: September 9, 2024].

9.Infectious Diseases Society of America. Position of the infectious diseases society of America and the HIV medicine association on team-based infectious diseases care and the roles of advanced practice providers and clinical pharmacists. Clinical Infectious Diseases 2024; doi: 10.1093/cid/ciae265

10. Sunagawa SW , Bares SH , Fadul N , et al. Letter: A longitudinal model of HIV clinical pharmacy service expansion: A decade-plus model of clinical expansion and practice integration. AIDS Patient Care STDS 2026;40(2):39–41; doi: 10.1177/10872914261415703

11. Sued O , Nardi N , Spadaccini L . Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: A scoping review. Curr Opin HIV AIDS 2022;17(3):145–161; doi: 10.1097/COH.0000000000000734

12. D’Amico R , Margolis DA . Long-acting injectable therapy. Curr Opin HIV AIDS 2020;15(1):13–18; doi: 10.1097/COH.0000000000000606